SkinBioTherapeutics plc, a life science group focused on skin health, has reported a 284% increase in full-year revenues to £4.6m.

The Newcastle firm said adjusted EBITDA was a £400k loss, narrowed from £2.1m in 2024, with an operating loss improvement of 61% to £1.1m (2024: £2.9m loss).

Market expectations for the year ending 30th June 2026 are revenue of £6.2m and adjusted EBITDA of £700,000.

Simon Hewitson, who only joined the company in April, stepped down as COO for personal reasons following the year-end period.

Emily Bertram, who was appointed group finance director in April, is to be promoted to CFO and also to the board.